Skip to main content
. Author manuscript; available in PMC: 2021 Apr 6.
Published in final edited form as: Cell Syst. 2020 Nov 18;11(5):449–460.e2. doi: 10.1016/j.cels.2020.09.003

Figure 3. Analysis of Larotrectinib by Tumor Tissue of Origin Finds Consistent Activity in Multiple Tumor Types, and Even Greater Activity in Infantile Fibrosarcoma.

Figure 3.

(A) Red line, observed average response; blue histogram, responses simulated according to the null hypothesis of no difference in response between tumors types.

(B) Observed responses that significantly exceed the null hypothesis, according to Benjamini-Hochberg procedure (to control the false discovery rate during multiple hypothesis testing), are indicated with +; N.S. denotes not significant. See also Table S2.